|
||||||
|
 | |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
| |
|
Gene: ENSG00000186205 |
Summary for MARC1 |
 Gene summary |
| Gene information | Ensembl ID | ENSG00000186205 | Gene symbol | MARC1 |
| Gene name | mitochondrial amidoxime reducing component 1 | |
| HGNC | 26189 | |
| Entrez ID | 64757 | |
| Gene type | protein_coding | |
| Synonyms | MTARC1|FLJ22390 | |
| UniProtAcc | Q5VT66 |
| Drugs associated with this gene(DrugBank). |
| Gene ID | Gene Symbol | Drug ID | Drug Name | Drug Type |
| Cancer therapeutic drugs associated with this gene(NCI). |
| Gene ID | Gene Name | Drug ID | Drug Name | Drug Type | Cancer |
Top |
Structure and expression level for MARC1 |
| AS events and RNA A-to-I editing events of the gene in TCGA based on Genvode V22 structure. ∗For more information on exon skipping events please check the ExonskipDB database. ∗For more information on exon skipping events please check the CAeditome database. |
 |
| Landscape of gene expressions across multiple cancer types. |
 |
| Differentially expressed gene analysis between tumor male and tumor female samples. |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| Differentially expressed gene analysis between tumor male and normal male samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MARC1 | 1.87e+03 | -2.49e+00 | 4.86e-01 | -5.14e+00 | 2.82e-07 | 2.28e-06 | CHOL |
| Differentially expressed gene analysis between tumor female and normal female samples. |
 |
| Coding Name | Base Mean | log2FoldChange | lfcSE | Stat | P value | P.adjust Value | Cancer Type |
| MARC1 | 1.59e+03 | -2.73e+00 | 1.09e-01 | -2.51e+01 | 1.30e-138 | 1.15e-136 | BRCA |
Top |
Sex-biased somatic mutation for MARC1 |
| ∗For more information on exon skipping events please check the ExonskipDB database. |
| Gene ID | Cancer Type | Hugo Symbol | Male | Female | pval | or | ci.up | ci.low | adjPval |
Top |
DNA methylation with beta values for MARC1 |
| Landscape of DNA methylation across multiple cancer types. |
 |
| Differentially expressed CpG sites between male tumor and female tumor patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| ACC | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 1.34e-01 | 2.61e-01 | -2.99e+00 | 2.77e-03 | 1.16e-02 | -1.27e-01 |
| ACC | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 2.49e-01 | 3.92e-01 | -2.57e+00 | 1.02e-02 | 2.57e-02 | -1.44e-01 |
| ACC | cg11245333 | chr1:220786589 | CGI:chr1:220786674-220787261 | promoter | 1.12e-01 | 2.15e-01 | -2.84e+00 | 4.49e-03 | 1.60e-02 | -1.03e-01 |
| Differentially expressed CpG sites between male tumor and male normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| LUAD | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 7.97e-01 | 9.06e-01 | -3.07e+00 | 2.17e-03 | 3.72e-03 | -1.09e-01 |
| THCA | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 4.80e-01 | 3.41e-01 | 3.09e+00 | 2.02e-03 | 5.21e-03 | 1.39e-01 |
| THCA | cg12581970 | chr1:220785885 | CGI:chr1:220786674-220787261 | promoter | 6.29e-01 | 4.90e-01 | 2.66e+00 | 7.72e-03 | 1.38e-02 | 1.40e-01 |
| THCA | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 3.19e-01 | 2.10e-01 | 2.99e+00 | 2.76e-03 | 6.54e-03 | 1.08e-01 |
| LUSC | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 6.55e-01 | 9.29e-01 | -4.23e+00 | 2.34e-05 | 5.26e-04 | -2.73e-01 |
| LUSC | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 3.72e-01 | 1.63e-01 | 2.77e+00 | 5.61e-03 | 8.90e-03 | 2.08e-01 |
| BLCA | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 3.84e-01 | 2.75e-01 | 2.03e+00 | 4.25e-02 | 4.41e-02 | 1.08e-01 |
| BLCA | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 5.59e-01 | 7.76e-01 | -2.69e+00 | 7.19e-03 | 1.09e-02 | -2.17e-01 |
| ESCA | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 4.13e-01 | 2.50e-01 | 2.39e+00 | 1.67e-02 | 3.90e-02 | 1.63e-01 |
| ESCA | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 3.38e-01 | 1.64e-01 | 2.39e+00 | 1.67e-02 | 3.90e-02 | 1.74e-01 |
| CHOL | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 3.64e-01 | 1.06e-01 | 2.95e+00 | 3.19e-03 | 1.32e-02 | 2.58e-01 |
| CHOL | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 8.26e-01 | 4.73e-01 | 3.10e+00 | 1.96e-03 | 1.07e-02 | 3.53e-01 |
| CHOL | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 3.03e-01 | 6.86e-02 | 2.73e+00 | 6.38e-03 | 1.82e-02 | 2.34e-01 |
| Differentially expressed CpG sites between female tumor and female normal patients. |
| Cancer Type | CpG Site | Position | CpG Island | Position to Gene | ave1 | ave2 | wilcoxon.w | wilcoxon.p | padj | dBeta |
| BRCA | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 5.64e-01 | 8.23e-01 | -1.10e+01 | 3.54e-28 | 4.16e-27 | -2.60e-01 |
| BRCA | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 4.63e-01 | 3.30e-01 | 6.41e+00 | 1.41e-10 | 3.66e-10 | 1.33e-01 |
| HNSC | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 7.35e-01 | 5.89e-01 | 2.12e+00 | 3.44e-02 | 3.88e-02 | 1.46e-01 |
| HNSC | cg07185695 | chr1:220786244 | CGI:chr1:220786674-220787261 | promoter | 4.21e-01 | 2.73e-01 | 2.68e+00 | 7.35e-03 | 1.59e-02 | 1.49e-01 |
| COAD | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 4.01e-01 | 2.80e-01 | 2.26e+00 | 2.35e-02 | 2.92e-02 | 1.21e-01 |
| COAD | cg04396721 | chr1:220785328 | CGI:chr1:220786674-220787261 | promoter | 5.62e-01 | 4.57e-01 | 2.03e+00 | 4.24e-02 | 4.43e-02 | 1.06e-01 |
| LIHC | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 2.62e-01 | 1.03e-01 | 4.94e+00 | 7.93e-07 | 1.13e-05 | 1.59e-01 |
| KIRP | cg09023136 | chr1:220786295 | CGI:chr1:220786674-220787261 | promoter | 4.36e-01 | 3.11e-01 | 2.23e+00 | 2.56e-02 | 3.16e-02 | 1.25e-01 |
| KIRP | cg11245333 | chr1:220786589 | CGI:chr1:220786674-220787261 | promoter | 1.79e-01 | 6.18e-02 | 2.82e+00 | 4.84e-03 | 1.04e-02 | 1.18e-01 |
Top |
Exon skipping events with PSI in TCGA for MARC1 |
| ∗Please access ExonSkipDB for exon skipping annotation. |
| Landscape of exon skipping events across multiple cancer types. |
 |
| Differentially expressed exon skipping events between male tumor and female tumor patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between male tumor and male normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
| Differentially expressed exon skipping events between female tumor and female normal patients. |
| Cancer Type | Exon Skipping | ave.female_T | ave.female_N | wilcoxon.w | wilcoxon.p | padj | dPSI |
Top |
RNA A-to-I editing events in TCGA for MARC1 |
| ∗Please access CAeditome for RNA editing annotation. |
| Landscape of RNA editing events across multiple cancer types. |
 |
| Differentially expressed RNA editing events between male tumor and female tumor patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| LGG | MARC1-001 | chr1_220817199_+ | 5.98e-01 | 5.13e-01 | 1.98e+00 | 4.82e-02 | 4.97e-02 | 8.49e-02 |
| Differentially expressed RNA editing events between male tumor and male normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| Differentially expressed RNA editing events between female tumor and female normal patients. |
| Cancer Type | Transcript | Editing | ave.male_T | ave.female_T | wilcoxon.w | wilcoxon.p | p_adj | dFre |
| BRCA | MARC1-001 | chr1_220814546_+ | 6.32e-01 | 4.38e-01 | 2.19e+00 | 2.86e-02 | 3.24e-02 | 1.93e-01 |
| Protein coding RNA editing(s). |
| Editing Position | Variant Type | Gene Symbol | Transcript ID | NTchange | AAchange |
Top |
Sex-biased TF-Gene network for MARC1 |
| TFs related to MARC1. ∗The female-biased TF-gene edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased TF-gene edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | TF | Target Gene | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| ACC | ZNF611 | MARC1 | 3.86e+00 | 9.81e-01 | 2.87e+00 | 4.15e-03 | Male-biased |
| LAML | ALX3 | MARC1 | 4.13e+00 | 1.42e-02 | 4.94e+00 | 9.81e-01 | Female-biased |
| LAML | ALX4 | MARC1 | 4.09e+00 | 1.49e-02 | 4.88e+00 | 9.80e-01 | Female-biased |
| PCPG | ALX1 | MARC1 | 2.83e+00 | 1.72e-03 | 4.01e+00 | 9.85e-01 | Female-biased |
| PCPG | ALX3 | MARC1 | 3.47e+00 | 4.13e-03 | 4.47e+00 | 9.89e-01 | Female-biased |
| PCPG | ALX4 | MARC1 | 3.43e+00 | 4.23e-03 | 4.42e+00 | 9.89e-01 | Female-biased |
| PCPG | DMRT3 | MARC1 | 3.12e+00 | 2.43e-03 | 4.24e+00 | 9.88e-01 | Female-biased |
| PCPG | EMX1 | MARC1 | 3.32e+00 | 3.73e-03 | 4.34e+00 | 9.88e-01 | Female-biased |
| PCPG | EMX2 | MARC1 | 3.04e+00 | 2.57e-03 | 4.14e+00 | 9.86e-01 | Female-biased |
| PCPG | FOXD2 | MARC1 | 2.49e+00 | 9.06e-04 | 3.80e+00 | 9.80e-01 | Female-biased |
| PCPG | FOXO1 | MARC1 | 2.83e+00 | 1.94e-03 | 3.99e+00 | 9.84e-01 | Female-biased |
| PCPG | FOXO4 | MARC1 | 3.36e+00 | 4.19e-03 | 4.36e+00 | 9.88e-01 | Female-biased |
| PCPG | HOXA9 | MARC1 | 3.05e+00 | 2.85e-03 | 4.12e+00 | 9.86e-01 | Female-biased |
| PCPG | HSFY1 | MARC1 | 3.42e+00 | 9.63e-03 | 4.23e+00 | 9.81e-01 | Female-biased |
| PCPG | LHX8 | MARC1 | 4.21e+00 | 5.72e-03 | 5.14e+00 | 9.92e-01 | Female-biased |
| PCPG | MSX1 | MARC1 | 2.60e+00 | 9.70e-04 | 3.90e+00 | 9.83e-01 | Female-biased |
| PCPG | MSX2 | MARC1 | 2.63e+00 | 9.00e-04 | 3.94e+00 | 9.84e-01 | Female-biased |
| PCPG | NKX3-1 | MARC1 | 2.81e+00 | 1.05e-03 | 4.09e+00 | 9.87e-01 | Female-biased |
| PCPG | PBX4 | MARC1 | 3.04e+00 | 1.97e-03 | 4.19e+00 | 9.88e-01 | Female-biased |
| PCPG | PHOX2B | MARC1 | 2.74e+00 | 2.09e-03 | 3.88e+00 | 9.81e-01 | Female-biased |
| PCPG | POU1F1 | MARC1 | 3.47e+00 | 5.42e-03 | 4.41e+00 | 9.87e-01 | Female-biased |
| PCPG | POU4F1 | MARC1 | 2.62e+00 | 1.30e-03 | 3.86e+00 | 9.82e-01 | Female-biased |
| PCPG | POU6F2 | MARC1 | 3.18e+00 | 1.97e-03 | 4.34e+00 | 9.90e-01 | Female-biased |
| PCPG | UNCX | MARC1 | 2.88e+00 | 1.58e-03 | 4.08e+00 | 9.86e-01 | Female-biased |
| PCPG | ZNF121 | MARC1 | 4.09e+00 | 9.85e-01 | 2.93e+00 | 1.93e-03 | Male-biased |
| PCPG | ZNF181 | MARC1 | 4.05e+00 | 9.85e-01 | 2.79e+00 | 1.13e-03 | Male-biased |
| PCPG | ZNF337 | MARC1 | 3.12e+00 | 6.09e-03 | 4.03e+00 | 9.81e-01 | Female-biased |
| PCPG | ZNF33A | MARC1 | 4.00e+00 | 9.83e-01 | 2.74e+00 | 1.12e-03 | Male-biased |
| PCPG | ZNF443 | MARC1 | 4.04e+00 | 9.83e-01 | 2.91e+00 | 2.16e-03 | Male-biased |
| PCPG | ZNF496 | MARC1 | 4.00e+00 | 9.80e-01 | 3.01e+00 | 4.17e-03 | Male-biased |
| PCPG | ZNF770 | MARC1 | 3.93e+00 | 9.82e-01 | 2.52e+00 | 5.14e-04 | Male-biased |
| SKCM | ALX3 | MARC1 | 3.37e+00 | 4.97e-03 | 4.57e+00 | 9.83e-01 | Female-biased |
| SKCM | ALX4 | MARC1 | 3.30e+00 | 4.40e-03 | 4.54e+00 | 9.83e-01 | Female-biased |
| SKCM | DMRT3 | MARC1 | 2.91e+00 | 2.39e-03 | 4.33e+00 | 9.81e-01 | Female-biased |
| SKCM | LHX8 | MARC1 | 4.41e+00 | 1.35e-02 | 5.29e+00 | 9.82e-01 | Female-biased |
| SKCM | POU6F2 | MARC1 | 2.91e+00 | 2.57e-03 | 4.31e+00 | 9.80e-01 | Female-biased |
| MARC1 related gene. ∗Only the gene encode TF might with this result. ∗For more information please check Sex-biased TF-Coding gene network. |
Top |
Sex-biased RBP-ES network for MARC1 |
| RBPs related to ES in MARC1. ∗The female-biased RBP-ES edges were identified if Female_Edge_threshold>0.98 and Male_Edge_threshold<=0.98. ∗The male-biased RBP-ES edges were identified if Male_Edge_threshold>0.98 and Female_Edge_threshold<=0.98. |
 |
| Cancer Type | RBP | Target ES | Male Edge Score | Male Edge Threshold | Female Edge Score | Female Edge Threshold | Type |
| GBM | RBM5 | exon_skip_18124 | 7.29e+00 | 6.96e-03 | 7.66e+00 | 9.83e-01 | Female-biased |
| MARC1 related ES. ∗Only the gene encode RBP might with this result. ∗For more information please check Sex-biased RBP-ES network in cancer. |
Top |
Sex-biased CeRNA regulation of gene |
| Sex-biased CeRNA regulation of gene. |
| Gene ID | ceRNA(lncRNA-miRNA-mRNA) | Group | Cancer Type |
Top |
Sex-biased eQTL regulation of gene |
| Sex-biased eQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| eQTL | Description |
| Male-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs75207721 | chr1:219186208:A:G | - | 0.147472095654625 | 0.000523547692699879 | BLCA | Female-baised eQTL |
| rs74884850 | chr1:219189335:A:T | - | 0.147472095654625 | 0.000523547692699879 | BLCA | Female-baised eQTL |
| rs17005274 | chr1:219315921:C:G | - | 0.13629204484176 | 0.00148679239007668 | BLCA | Female-baised eQTL |
| rs111931211 | chr1:219260658:A:C | - | 0.145049082742775 | 0.00328885040542001 | BLCA | Female-baised eQTL |
| rs199624969 | chr1:219115195:C:T | - | 0.112625904230782 | 0.00379534594903345 | BLCA | Female-baised eQTL |
| rs10863429 | chr1:219126452:T:C | - | 0.112625904230782 | 0.00379534594903345 | BLCA | Female-baised eQTL |
| rs7554296 | chr1:219127795:G:A | - | 0.11251612257266 | 0.00398738756202017 | BLCA | Female-baised eQTL |
| rs74138343 | chr1:219128194:A:G | - | 0.11251612257266 | 0.00398738756202017 | BLCA | Female-baised eQTL |
| rs17525419 | chr1:219341156:A:G | - | 0.160392107436432 | 0.00479319673801716 | BLCA | Female-baised eQTL |
| rs111522904 | chr1:219352256:C:T | - | 0.160392107436432 | 0.00479319673801716 | BLCA | Female-baised eQTL |
| rs12058065 | chr1:219116156:A:G | - | 0.10952360942452 | 0.00511767369366289 | BLCA | Female-baised eQTL |
| rs12068797 | chr1:219116645:C:T | - | 0.10952360942452 | 0.00511767369366289 | BLCA | Female-baised eQTL |
| rs12070184 | chr1:219117360:C:G | - | 0.10952360942452 | 0.00511767369366289 | BLCA | Female-baised eQTL |
| rs6689395 | chr1:219118870:G:A | - | 0.10952360942452 | 0.00511767369366289 | BLCA | Female-baised eQTL |
| rs74138160 | chr1:219120154:G:A | - | 0.10952360942452 | 0.00511767369366289 | BLCA | Female-baised eQTL |
| rs6688817 | chr1:219124301:G:A | - | 0.10952360942452 | 0.00511767369366289 | BLCA | Female-baised eQTL |
| rs112221644 | chr1:219365468:T:C | - | 0.142218972001124 | 0.00666196896895799 | BLCA | Female-baised eQTL |
| rs11801581 | chr1:219374404:C:T | - | 0.142218972001124 | 0.00666196896895799 | BLCA | Female-baised eQTL |
| rs76910548 | chr1:219378283:G:C | - | 0.142218972001124 | 0.00666196896895799 | BLCA | Female-baised eQTL |
| rs75060212 | chr1:219172269:T:G | - | 0.110128996966254 | 0.00745376921557698 | BLCA | Female-baised eQTL |
| rs17526679 | chr1:219380975:G:A | - | 0.139281120944505 | 0.00780970783338518 | BLCA | Female-baised eQTL |
| rs73099168 | chr1:219381197:A:G | - | 0.139281120944505 | 0.00780970783338518 | BLCA | Female-baised eQTL |
| rs10495123 | chr1:219384317:C:T | - | 0.139281120944505 | 0.00780970783338518 | BLCA | Female-baised eQTL |
| rs17005378 | chr1:219390002:T:G | - | 0.139281120944505 | 0.00780970783338518 | BLCA | Female-baised eQTL |
| rs140709316 | chr1:219411042:C:T | - | 0.139389654757468 | 0.00947511871226712 | BLCA | Female-baised eQTL |
| rs7545730 | chr1:219084539:T:C | - | 0.104043192901498 | 0.0100603352378236 | BLCA | Female-baised eQTL |
| rs74138157 | chr1:219088539:A:G | - | 0.104043192901498 | 0.0100603352378236 | BLCA | Female-baised eQTL |
| rs77788767 | chr1:219090109:G:T | - | 0.104043192901498 | 0.0100603352378236 | BLCA | Female-baised eQTL |
| rs6666109 | chr1:219375031:C:T | - | 0.117387866748316 | 0.0114293721781146 | BLCA | Female-baised eQTL |
| rs17592209 | chr1:219375148:A:G | - | 0.117387866748316 | 0.0114293721781146 | BLCA | Female-baised eQTL |
| rs74549727 | chr1:219377287:A:G | - | 0.117387866748316 | 0.0114293721781146 | BLCA | Female-baised eQTL |
| rs78046192 | chr1:219377394:A:G | - | 0.117387866748316 | 0.0114293721781146 | BLCA | Female-baised eQTL |
| rs7543820 | chr1:219134557:G:A | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs7553226 | chr1:219135207:C:T | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs11118223 | chr1:219144418:T:C | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs58580269 | chr1:219146476:G:A | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs7523306 | chr1:219147504:G:A | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs12079503 | chr1:219149936:T:C | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs7541894 | chr1:219153697:T:C | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs6657059 | chr1:219158716:T:G | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs11118229 | chr1:219159955:C:T | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs3748634 | chr1:219163745:A:T | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs3748635 | chr1:219163746:A:T | - | 0.10705608802676 | 0.0115053033351999 | BLCA | Female-baised eQTL |
| rs7539768 | chr1:219147837:T:G | - | 0.105997702771658 | 0.0116290045050833 | BLCA | Female-baised eQTL |
| rs190814059 | chr1:219102734:G:A | - | 0.101200000884594 | 0.0131489216028602 | BLCA | Female-baised eQTL |
| rs202025384 | chr1:219104413:G:C | - | 0.101200000884594 | 0.0131489216028602 | BLCA | Female-baised eQTL |
| rs6699816 | chr1:219182447:A:G | - | 0.105034066855616 | 0.0143615684508211 | BLCA | Female-baised eQTL |
| rs6701914 | chr1:219187557:T:A | - | 0.105034066855616 | 0.0143615684508211 | BLCA | Female-baised eQTL |
| rs12093892 | chr1:219195006:G:T | - | 0.105034066855616 | 0.0143615684508211 | BLCA | Female-baised eQTL |
| rs6656247 | chr1:219229352:G:A | - | 0.105034066855616 | 0.0143615684508211 | BLCA | Female-baised eQTL |
| rs59079627 | chr1:219277694:T:G | - | 0.105590240526385 | 0.0144086913025425 | BLCA | Female-baised eQTL |
| rs6676688 | chr1:219285577:G:A | - | 0.105590240526385 | 0.0144086913025425 | BLCA | Female-baised eQTL |
| rs12080335 | chr1:219286645:T:C | - | 0.105590240526385 | 0.0144086913025425 | BLCA | Female-baised eQTL |
| rs17005229 | chr1:219290142:G:A | - | 0.105590240526385 | 0.0144086913025425 | BLCA | Female-baised eQTL |
| rs11118207 | chr1:219096456:C:T | - | 0.101840053656414 | 0.0151116889449629 | BLCA | Female-baised eQTL |
| rs1869760 | chr1:219403509:T:A | - | 0.133909925313403 | 0.0151553095249706 | BLCA | Female-baised eQTL |
| rs73101412 | chr1:219404029:C:T | - | 0.133909925313403 | 0.0151553095249706 | BLCA | Female-baised eQTL |
| rs17005406 | chr1:219406588:A:G | - | 0.133909925313403 | 0.0151553095249706 | BLCA | Female-baised eQTL |
| rs73110551 | chr1:219290525:C:G | - | 0.105252354049523 | 0.0158607005818192 | BLCA | Female-baised eQTL |
| rs1531089 | chr1:219369630:C:T | - | 0.126074499935486 | 0.0243611584295454 | BLCA | Female-baised eQTL |
| rs11118205 | chr1:219089444:C:T | - | 0.0939774600687989 | 0.0276292652561011 | BLCA | Female-baised eQTL |
| rs12039827 | chr1:219094897:A:C | - | 0.0939774600687989 | 0.0276292652561011 | BLCA | Female-baised eQTL |
| rs6656781 | chr1:219098701:G:A | - | 0.0939774600687989 | 0.0276292652561011 | BLCA | Female-baised eQTL |
| rs6659896 | chr1:219192079:C:T | - | 0.0905660725918251 | 0.0480772748087586 | BLCA | Female-baised eQTL |
| rs76986060 | chr1:219354133:A:G | - | 0.125723045966642 | 0.0496151082287137 | BLCA | Female-baised eQTL |
| rs61358910 | chr1:219355140:C:A | - | 0.125723045966642 | 0.0496151082287137 | BLCA | Female-baised eQTL |
| rs12067814 | chr1:212473792:T:G | - | 0.0746675324058737 | 0.00632557113024391 | LUAD | Female-baised eQTL |
| rs7416455 | chr1:221048057:C:A | - | 0.0771950020285969 | 0.00653467904603216 | LUAD | Female-baised eQTL |
| rs6694503 | chr1:212472657:C:A | - | 0.0727220414183696 | 0.0111148292544502 | LUAD | Female-baised eQTL |
| rs6697091 | chr1:212472883:C:A | - | 0.0727220414183696 | 0.0111148292544502 | LUAD | Female-baised eQTL |
| rs13374814 | chr1:212476883:T:C | - | 0.0709292994510338 | 0.0118631864608477 | LUAD | Female-baised eQTL |
| rs10863585 | chr1:221123784:G:C | - | -0.0660207919578451 | 0.0227408591725195 | LUAD | Female-baised eQTL |
| rs7527151 | chr1:221068378:C:T | - | -0.0653878892507175 | 0.0270116455873739 | LUAD | Female-baised eQTL |
| rs1867071 | chr1:221069936:T:A | - | -0.0653878892507175 | 0.0270116455873739 | LUAD | Female-baised eQTL |
| rs11118656 | chr1:221131006:A:G | - | -0.0647321407529655 | 0.0282157649626633 | LUAD | Female-baised eQTL |
| rs1592081 | chr1:221131356:A:G | - | -0.0647321407529655 | 0.0282157649626633 | LUAD | Female-baised eQTL |
| rs10779423 | chr1:221131824:A:G | - | -0.0647321407529655 | 0.0282157649626633 | LUAD | Female-baised eQTL |
| rs1417921 | chr1:221134969:G:A | - | -0.0642600165584778 | 0.0293034593088542 | LUAD | Female-baised eQTL |
| rs7527891 | chr1:221093910:T:C | - | -0.0642227156214288 | 0.0294800932200029 | LUAD | Female-baised eQTL |
| rs6541173 | chr1:221129975:C:G | - | -0.0639883916520732 | 0.0305102853028662 | LUAD | Female-baised eQTL |
| rs1360885 | chr1:221004877:C:A | - | 0.0422817661496306 | 0.0319648816887364 | LUAD | Female-baised eQTL |
| rs1360886 | chr1:221004878:C:G | - | 0.0422817661496306 | 0.0319648816887364 | LUAD | Female-baised eQTL |
| rs7513152 | chr1:221071056:G:A | - | -0.0631679591958948 | 0.0347269121122216 | LUAD | Female-baised eQTL |
| rs12568940 | chr1:221096252:A:G | - | -0.0631679591958948 | 0.0347269121122216 | LUAD | Female-baised eQTL |
| rs10218738 | chr1:221106752:C:T | - | -0.0631679591958948 | 0.0347269121122216 | LUAD | Female-baised eQTL |
| rs10746408 | chr1:221108179:C:T | - | -0.0631679591958948 | 0.0347269121122216 | LUAD | Female-baised eQTL |
| rs1073166 | chr1:221110479:T:C | - | -0.0631679591958948 | 0.0347269121122216 | LUAD | Female-baised eQTL |
| rs989463 | chr1:221118655:T:A | - | -0.0631679591958948 | 0.0347269121122216 | LUAD | Female-baised eQTL |
| rs6694121 | chr1:221076051:A:G | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs6656596 | chr1:221076070:G:A | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs10863582 | chr1:221096680:T:C | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs6541172 | chr1:221100362:G:T | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs10218739 | chr1:221106630:G:A | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs1372665 | chr1:221111074:C:T | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs1965817 | chr1:221115702:T:C | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs10779421 | chr1:221119897:A:T | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs10863584 | chr1:221123765:G:T | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs1561834 | chr1:221124827:G:A | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs3939727 | chr1:221128526:C:A | - | -0.0624537481809053 | 0.037386459433793 | LUAD | Female-baised eQTL |
| rs11118650 | chr1:221084770:A:G | - | -0.0630766288941505 | 0.0431009700142989 | LUAD | Female-baised eQTL |
| rs894361 | chr1:221086949:T:A | - | -0.0630766288941505 | 0.0431009700142989 | LUAD | Female-baised eQTL |
| rs1992480 | chr1:221087945:A:G | - | -0.0630766288941505 | 0.0431009700142989 | LUAD | Female-baised eQTL |
| rs6669742 | chr1:221091896:C:T | - | -0.0630766288941505 | 0.0431009700142989 | LUAD | Female-baised eQTL |
| rs12091487 | chr1:221153123:A:G | - | -0.0591315697568253 | 0.0431946813147978 | LUAD | Female-baised eQTL |
| rs4142388 | chr1:221142456:G:T | - | -0.0587412045871194 | 0.043698725625726 | LUAD | Female-baised eQTL |
| rs1539139 | chr1:221143680:G:A | - | -0.0587412045871194 | 0.043698725625726 | LUAD | Female-baised eQTL |
| rs6541176 | chr1:221145976:C:T | - | -0.0587412045871194 | 0.043698725625726 | LUAD | Female-baised eQTL |
| rs6541177 | chr1:221145987:A:C | - | -0.0587412045871194 | 0.043698725625726 | LUAD | Female-baised eQTL |
| rs6541178 | chr1:221146007:A:C | - | -0.0587412045871194 | 0.043698725625726 | LUAD | Female-baised eQTL |
| rs9431421 | chr1:221157643:G:A | - | -0.05895203429407 | 0.0446446233725387 | LUAD | Female-baised eQTL |
| rs6541179 | chr1:221159271:A:G | - | -0.05895203429407 | 0.0446446233725387 | LUAD | Female-baised eQTL |
| rs6657690 | chr1:221164292:C:T | - | -0.05895203429407 | 0.0446446233725387 | LUAD | Female-baised eQTL |
| rs111504698 | chr1:221053466:T:C | - | 0.0556665498104759 | 0.0458726810078049 | LUAD | Female-baised eQTL |
| rs7545437 | chr1:221079491:C:G | - | -0.0623264345802458 | 0.0462929248127264 | LUAD | Female-baised eQTL |
| rs12139572 | chr1:221081730:A:C | - | -0.0623264345802458 | 0.0462929248127264 | LUAD | Female-baised eQTL |
| rs10863580 | chr1:221091235:T:C | - | -0.0623264345802458 | 0.0462929248127264 | LUAD | Female-baised eQTL |
| Female-specific eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Effect Score | FDR | Cancer Type | Biased Type |
| rs75988682 | chr1:228843588:C:T | - | 0.203042829056417 | 0.0429108771359365 | THCA | Male-baised eQTL |
| rs111395032 | chr1:228847473:G:C | - | 0.203042829056417 | 0.0429108771359365 | THCA | Male-baised eQTL |
| rs78054379 | chr1:228847802:C:G | - | 0.203042829056417 | 0.0429108771359365 | THCA | Male-baised eQTL |
| rs77508362 | chr1:228848659:C:T | - | 0.203042829056417 | 0.0429108771359365 | THCA | Male-baised eQTL |
| rs1493085 | chr1:228851318:T:C | - | 0.203042829056417 | 0.0429108771359365 | THCA | Male-baised eQTL |
| rs3103804 | chr1:228844077:A:G | - | 0.193608299608558 | 0.0457620008614454 | THCA | Male-baised eQTL |
| rs3103802 | chr1:228844140:T:C | - | 0.193608299608558 | 0.0457620008614454 | THCA | Male-baised eQTL |
| rs2639768 | chr1:228844654:G:A | - | 0.193608299608558 | 0.0457620008614454 | THCA | Male-baised eQTL |
| rs2639767 | chr1:228844899:T:C | - | 0.193608299608558 | 0.0457620008614454 | THCA | Male-baised eQTL |
| rs78118675 | chr1:228849704:C:T | - | 0.201644211034963 | 0.0480414159593963 | THCA | Male-baised eQTL |
| rs853755 | chr1:213901764:G:T | - | -0.101321030806029 | 0.0148729982783127 | KIRC | Male-baised eQTL |
| rs6666762 | chr1:216549035:T:C | - | 0.0563717437214793 | 0.000254485489916897 | BLCA | Male-baised eQTL |
| rs6604636 | chr1:216551385:T:C | - | 0.0562206506067963 | 0.000327202645070376 | BLCA | Male-baised eQTL |
| rs2647116 | chr1:218836493:G:A | - | 0.0256352107244315 | 0.0196451986056446 | BLCA | Male-baised eQTL |
| rs2647117 | chr1:218836199:C:G | - | 0.0252052873163594 | 0.0260132264009053 | BLCA | Male-baised eQTL |
| rs2816335 | chr1:225958648:T:C | - | -0.0441135148018447 | 0.027323160157313 | BLCA | Male-baised eQTL |
| rs10465675 | chr1:218819829:G:T | - | 0.023688379959418 | 0.0418910612276907 | BLCA | Male-baised eQTL |
| rs7552186 | chr1:218821931:C:T | - | 0.023688379959418 | 0.0418910612276907 | BLCA | Male-baised eQTL |
| rs2378023 | chr1:218824090:G:A | - | 0.023688379959418 | 0.0418910612276907 | BLCA | Male-baised eQTL |
| rs7515675 | chr1:218826087:A:G | - | 0.023688379959418 | 0.0418910612276907 | BLCA | Male-baised eQTL |
| rs2803889 | chr1:218829940:G:T | - | 0.023688379959418 | 0.0418910612276907 | BLCA | Male-baised eQTL |
| rs7538841 | chr1:217646038:A:G | - | 0.0295471538666638 | 0.0467917790037968 | BLCA | Male-baised eQTL |
| rs7527314 | chr1:217646215:C:T | - | 0.0295471538666638 | 0.0467917790037968 | BLCA | Male-baised eQTL |
| rs2378022 | chr1:218817475:G:A | - | 0.0228232875439144 | 0.0487047536278644 | BLCA | Male-baised eQTL |
| Opposite sex-biased eQTL regulation. |
| SNP ID | SNP Info | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Sex-biased Gene in Cancer | Cancer Type |
Top |
Sex-biased eQTM regulation of gene |
| Sex-biased eQTM regulation of gene (The figures only show the pairs with FDR<1e-5. For more information please check the below table). |
| eQTM | Description |
 | Gene ID: ENSG00000186205 |
| CpG Site: cg14840487 | |
| Position to Gene: gene,enhancer | |
| Male Effect: -0.445729947208296 | |
| Female Effect: - |
| Male-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| cg14840487 | chr1:220789528 | gene,enhancer | -0.445729947208296 | 1.49989894376231e-07 | -0.4038779637287587 | 3.697901766942322e-10 | LUAD |
| Female-specific eQTM regulation. |
| CpG Site | CpG Postion | Position to Gene | Effect Score | FDR | Cor.r | Cor.Pvalue | Cancer Type |
| Opposite sex-biased eQTM regulation. |
| CpG Site | CpG Postion | CpG Island | Position to Gene | Male Effect | Male FDR | Female Effect | Female FDR | Male Cor | Male P-value | Female Cor | Female P-value | Sex-biased Coding Gene | Cancer Type |
Top |
Sex-biased sQTL regulation of gene |
| Sex-biased sQTL regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTL | Description |
| Male-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Female-specific sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Effect Score | FDR | Cancer Type | Biased Type |
| Opposite sex-biased sQTL regulation. |
| ES ID | Skipped Exon | ORF Anno | SNP ID | SNP Info | SNP Position to ES | Male Effect | Male FDR | Female Effect | Female FDR | Cancer Type |
Top |
Sex-biased sQTM regulation of gene |
| Sex-biased sQTM regulation of gene (The figures only show the pairs with FDR <1e-5. For more information please check the below table). |
| sQTM | Description |
| Male-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Female-specific sQTM regulation. |
| EX ID | Skipped Exon | CPG Site | CPG Position | Position to EX Events | Effect Score | FDR | Cor.r | Cor.Pvalue | ORF_anno | Cancer Type |
| Opposite sex-biased sQTM regulation. |
| EX ID | EX Info | Skipped Exon | CPG Site | CPG Position | CPG Island | Position to EX Events | Male Effect | Male FDR | Female Effect | Female FDR | Male Correlation | Male P-value | Female Correlation | Female P-value | ORF_anno | Cancer Type |
Top |
Related disease information of MARC1 |
| Diseases associated with this gene (DisGeNET). |
| Gene ID | Gene Symbol | Disease ID | Disease Name | Number of PMID | Source |
